(W3) Are Patients Getting a Fair Share of the Value of Biosimilars?

Tuesday, October 15, 2024

3:30 PM – 4:45 PM PT

Location: 112

ACPE UAN:0233-0000-24-052-L01-P | Contact Hours: 1.25 | Activity Type: Knowledge-based

Faculty(s)

Rebekah SM Angove, PhD

EVP Research & Evaluation
Patient Advocate Foundation
Hampton, VA
James D. Chambers, PhD

Professor
Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center
Boston, MA
Javier Gonzalez, PharmD

Chief Growth and Commercial Officer
Abarca Health
San Juan, Puerto Rico

Moderator(s)

Cate Lockhart, PharmD, PhD

Chief Science Officer & Executive Director
AMCP & BBCIC
Alexandria, Virginia

The number of biosimilar products available in the United States continues to increase, but utilization remains variable for many, impacting patient access to important biologics. Furthermore, market dynamics and misaligned incentives influence treatment and coverage decisions. Biosimilars have demonstrated cost savings to the health care system, but those savings rarely reach the patient in the form of reduced out-of-pocket costs. There are some examples both within and outside the U.S. where payer policies had a positive impact on biosimilar utilization that ultimately result in cost savings and improvement in patient access to biologic therapies.

This session will provide insight into current biosimilar dynamics in the U.S., discuss the patient experience with biosimilars, and describe successful strategies for incentivizing biosimilar utilization.

Learning Objectives:

At the completion of this activity, participants should be able to:

Explain how aligning incentives could improve patient access to biosimilars.
Describe market dynamics that are affecting biosimilar utilization in the United States.
Discuss managed care approaches to support biosimilar utilization and patient access to treatment.